☆ 4.7 Article

Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients Receiving Concomitant 225Ac-DOTATATE-Targeted a-Therapy and Capecitabine: A Real-World-Scenario Management-Based Long-Term Outcome Study

JOURNAL OF NUCLEAR MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)

Mina M. Swiha et al.

Summary: Lu-177-Dotatate treatment outcomes are influenced by factors such as the presence of bone metastases, tumor type, and ascites occurrence. A high burden of skeletal and hepatic metastases and the existence of unusual metastatic locations negatively impact patient survival.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

Add to Collection

Review Oncology

Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis

Jonathan Strosberg et al.

Summary: Re-treatment with Lu-177-PRRT showed encouraging median PFS in patients with NETs, with a safety profile similar to initial PRRT.

CANCER TREATMENT REVIEWS (2021)

Add to Collection

Article Oncology

177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial

Jonathan R. Strosberg et al.

Summary: The NETTER-1 trial did not show a significant improvement in median overall survival with Lu-177-Dotatate treatment compared to high-dose long-acting octreotide, however, there was an 11.7 month difference which could be considered clinically relevant. No new safety signals were reported during long-term follow-up.

LANCET ONCOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review

Baptiste Camus et al.

Summary: Radionuclide therapy for neuroendocrine tumors, targeting tumor cells with a large quantity of somatostatin receptors, is effective and has shown significant efficacy in metastatic midgut neuroendocrine tumors. Besides midgut tumors, pancreatic and pulmonary neuroendocrine tumors also seem to benefit from this treatment approach.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Review Gastroenterology & Hepatology

Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot

Cornelius J. Fernandez et al.

Summary: Significant advancements have been made in the epidemiological, pathogenic, molecular diagnostic, and targeted therapeutic aspects of neuroendocrine neoplasms (NENs) over the past decade. NENs, which mainly originate from enteroendocrine cells of the embryonic gut, are characterized by slow growth and specific neuroendocrine biomarkers for diagnosis. Various biomarkers are used for the diagnosis and monitoring of treatment response in NENs.

WORLD JOURNAL OF GASTROINTESTINAL SURGERY (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity

Clemens Kratochwil et al.

Summary: This retrospective analysis aimed to estimate appropriate doses of Ac-225-DOTATOC in patients with somatostatin-receptor-expressing cancers. Results showed that a dose of approximately 20 MBq per cycle could avoid severe hematotoxicity, but might lead to chronic renal toxicity. Further research is needed to define safety thresholds of Ac-225-DOTATOC more precisely.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety

Sanjana Ballal et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)

Add to Collection

Article Oncology

Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival

S. Rudisile et al.

BMC CANCER (2019)

Add to Collection

Article Endocrinology & Metabolism

Targeted Alpha Particle Therapy for Neuroendocrine Tumours: The Next Generation of Peptide Receptor Radionuclide Therapy

Shaunak Navalkissoor et al.

NEUROENDOCRINOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

J. Strosberg et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients With Advanced Neuroendocrine Tumors A Long-term-Outcome, Toxicity, Survival, and Quality-of-Life Study

Sanjana Ballal et al.

CLINICAL NUCLEAR MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

James C. Yao et al.

LANCET (2016)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with L-lysine

Ho Sze Chan et al.

EJNMMI RESEARCH (2016)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotate

Ho Sze Chan et al.

EJNMMI RESEARCH (2016)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience

C. Kratochwil et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study

Lisa Bodei et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)

Add to Collection

Article Medicine, General & Internal

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.

Eric Raymond et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Article Oncology

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

Anja Rinke et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

Richard L. Wahl et al.

JOURNAL OF NUCLEAR MEDICINE (2009)

Add to Collection

Article Oncology

Preclinical evaluation of the α-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors

Matthias Miederer et al.

CLINICAL CANCER RESEARCH (2008)

Add to Collection

Article Endocrinology & Metabolism

Molecular targeted therapy for carcinoid and islet-cell carcinoma

James C. Yao

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2007)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Somatostatin-receptor-targeted α-emitting 213Bi is therapeutically more effective than β-emitting 177Lu in human pancreatic adenocarcinoma cells

Tapan K. Nayak et al.

NUCLEAR MEDICINE AND BIOLOGY (2007)

Add to Collection

Article Oncology

213Bi-[DOTA0,Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model

JP Norenberg et al.

CLINICAL CANCER RESEARCH (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.